Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metastatic melanoma treatment faces challenges due to acquired resistance to BRAF inhibitors.
• Targeting multiple cancer growth pathways simultaneously may overcome resistance.
• BRAF V600E mutation drives melanoma proliferation via the ERK MAPK pathway.

Purpose of the Study:

• Identify novel compounds that inhibit key proliferative pathways in BRAF V600E mutated melanoma.
• Investigate the dual inhibitory effects of pyridinyl imidazole compounds on melanoma cell signaling.
• Explore the impact of these compounds on the endolysosomal pathway and cellular stress responses.

Main Methods:

• Screening of pyridinyl imidazole compounds for dual inhibition of BRAF V600E and mTORC1 signaling.
• Analysis of extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) activity.
• Assessment of endolysosomal pathway integrity and mTORC1 localization using microscopy and biochemical assays.
• Evaluation of melanoma cell sensitivity to endoplasmic reticulum (ER) stress.

Main Results:

• Pyridinyl imidazole compounds SB202190, SB203580, and SB590885 were identified as dual inhibitors.
• These compounds directly inhibit BRAF V600E kinase and disrupt ERK MAPK signaling.
• Melanoma cells treated with these compounds showed disrupted endolysosomal compartments and altered mTORC1 signaling.
• The compounds induced sensitivity to endoplasmic reticulum (ER) stress in melanoma cells.

Conclusions:

• Pyridinyl imidazole compounds represent a promising therapeutic strategy for metastatic melanoma.
• Dual inhibition of BRAF V600E and mTORC1 pathways via endolysosomal disruption is a viable approach.
• These findings provide a rationale for developing pyridinyl imidazole-based anti-melanoma drugs.